medigraphic.com

2002, Number 4

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2002; 40 (4)

Type 2 Diabetes Mellitus Control. Hyperglucose Index As Indicator

Gómez LV, Zúñiga GS, García LE, Couttolenc LMI

Language: Spanish
References: 20
Page: 281-284
PDF size: 104.39 Kb.


ABSTRACT

Objective: To determine whether high glucose index is an alternative and reliable diagnostic method to evaluate control of patients type 2 with diabetes mellitus. Material and methods: We carried out a transversal, prospective, and comparative study in 90 persons with type 2 diabetes mellitus in which HbAlc was determined. Based on these results, patients were divided into two groups; one group was constituted of patients with HbAlc of ≥ 8 %; this group was identified as patients without control of glucose and the other group whose totals were below this value was considered patients with glucose control. Afterward, high glucose index was calculated in both groups, obtained dividing total glucose on an empty stomach equal to or more than 140 mg/dL by total glucose during the last 3 months. When high glucose index resulted 0.5 or more, we considered that the patient did not have glucose control. A contingency table of 2 x 2 was used to evaluate validity of high glucose index. Sensitivity, specificity and positive and negative values were determined. Confidence intervals of 95% (IC 95 %) were calculated to determine sensitivity and specific reliability. Results: 70 % of studied patients showed HbAlc totals without glucose control, which corresponds to the epidemiologic reality of this disease. We obtained a sensitivity of high glucose index of 60.3 % (IC 95 % = 50.2 to 69.8 %), a specificity of 77 % (IC 95 % = 69.2 % to 84.8 %), a positive value of 86.4, and a negative value of 45.6 %. Accuracy was 65.5%. Conclusions: High glucose index (HGI) does not constitute a useful parameter to value glucose control in diabetic patients because it shows a high rate of false negatives.


REFERENCES

  1. 1. Alleyne G. La diabetes: una declaración para las Américas. Bol Oficina Sanit Panam 1996;121:461-466.

  2. 2. Zárate-Treviño A. Algunas consideraciones históricas del diagnóstico de la diabetes mellitus. Gac Med Mex 1995;131:191-195.

  3. 3. Asociación Americana de Diabetes. Implicaciones del estudio sobre el control y las complicaciones de la diabetes. Diabetes Care 1996;19(Supl 1):50S-52S.

  4. 4. Dagogo-Jack S, Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic inter-ventions. Arch Intern Med 1997;157:1802-1814.

  5. 5. Escobedo-de-la-Peña J, Rico-Verdín B. Incidencia y letalidad de las complicaciones agudas y crónicas de la diabetes mellitus en México. Salud Publica Mex 1996;38:236-242.

  6. 6. López-Antuñano S, López-Antuñano FJ. Diabetes mellitus y lesiones del pie. Salud Publica Mex 1998;40:282-292.

  7. 7. Revilla-Monsalve MC, Arreola F, Castro-Martínez G, Escobedo-de-la-Peña J, Fiorelli S, Gutiérrez C, et al. Pruebas de laboratorio útiles para el control de la diabetes mellitus. Hemoglobina glucosilada. Rev Med IMSS 1995;33(5):501-504.

  8. 8. Méndez JD, Arreola F, Castro G, Escobedo-de la Peña J, Fiorelli S, Gutiérrez C, et al. Glicosilación de hemoglobinas. Rev Med IMSS 1994;32(2):183-185.

  9. 9. Ariza-Andraca R, Frati-Munari A, Alfaro-Mejía A, Casarrubias-Ramírez M, Florenzano-García A, Gayosso-Rivera A, et al. Diabetes mellitus no dependiente de insulina. Actualidades en Medicina Interna 1998;(6):2-15.

  10. Gabbay KH. Hemoglobina glucosilada y diabetes sacarina. En: Raskin P, editor. Clínicas Médicas de Norteamérica. México: Nueva Editorial Interame-ricana; 1982;6:1259-1264.

  11. Rodríguez-Rivera JG. Monitorización del control en el paciente diabético. En: Gómez-Pérez FJ, Rull JA, editores. Tratado de diabetología. México: Instituto Nacional de la Nutrición “Salvador Zubirán”; 1997. p. 403-416.

  12. Foster DW. Diabetes mellitus En: Braundwald E, Isselbacher K, Petersdorf R, Wilson J, Martin J, Fauci A. Harrison: principios de medicina interna. Décima cuarta edición. España: McGraw-Hill-Interamericana; 1998. p. 2341-2364.

  13. Asociación Americana de Diabetes. Estándares de los cuidados médicos para los pacientes con diabetes mellitus. Diabetes Care 1996;19(Supl 1):8S-15S.

  14. Heras-Martini R, Macías-González RC, Araiz-del- Rosario R. Diabetes mellitus: complicaciones crónicas y factores de riesgo. Rev Med IMSS 1996;34(6):449-455.

  15. American Diabetes Association. Implicaciones del estudio clínico sobre el control y las complicaciones de la diabetes. Diabetes Care 2000;23(Supl):S24-S26.

  16. UKPDS Group. UK prospective diabetes study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;325:837-852.

  17. Lee-Santos I, Martínez-Sánchez S, Ruiz-Ortiz L, López- Hernández MA. Impacto de la atención sistematizada en el control metabólico del paciente diabético tipo II. Rev Invest Med SSa 1997;2(2):47-50.

  18. Equipo de Trabajo del Programa del Adulto Mayor. Diabetes mellitus. Programas Básicos de Salud. SEMFYC: Doyma; 1998.

  19. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes. Lancet 1998; 352:854-865.

  20. Bailey C, Turner Robert C. Drug therapy: Metformin. N Engl J Med 1996;334(9):574-579.




2020     |     www.medigraphic.com